Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
ThinkAdvisor
A nurse pushes a patient on a gurney through a hospital corridor

Life Health > Health Insurance

Fight Against Future Supergerms Heats Up

X
Your article was successfully shared with the contacts you provided.

Drug makers around the world are asking insurers and other companies to help them to speed up the development of antibiotics and other antimicrobials.

The International Federation of Pharmaceutical Manufacturers and Associations wants help with getting the Group of 20 — an organization for 19 of the world’s richest countries, the European Union and the African Union — to support efforts to develop antibiotics that may have relatively low sales totals but be critical to preventing the spread of deadly antibiotic-resistant bacteria.

The world’s drug makers received approvals for just two new innovative antibiotics between 2017 and 2023, and federal analysts believe that drug makers could have just six antibiotics ready for approval between in 2033, according to a new federation report.

Adding stronger incentives and research support programs could increase the number of antibiotics that are ready for approval in 2033 to more than 40, the federation says.

Foreign Policy and the federation held a briefing on the supergerm problem Tuesday in New York.

What it means: Some of the same people who suggested before COVID-19 that pandemic preparedness was a good idea would like help with keeping antibiotic-resistant bacteria from starting a new pandemic.

Drug-resistant infections: Janelle Krishnamoorthy, head of global public policy at Merck, said that the people asking for help with fighting antimicrobial resistance have to work harder than before to get attention.

“It’s hard even to keep health as a priority,” Krishnamoorthy said. “People are like, ‘Let’s move on and look at other issues.”

But the U.S. Centers for Disease Control and Prevention estimates that drug-resistant infections already affect more than 2.8 million Americans per year and kill about 35,000 per year.

Amanda Jezek, a vice president at the Infectious Disease Society of America, said during a panel discussion that six drug-resistant pathogens cause about $4 billion in U.S. hospital bills per year.

America’s Health Insurance Plans, a group for health insurers, has been active in efforts to support the fight against antimicrobial resistance and put out a paper on the topic in 2019.

Drug cost: Ramanan Laxminarayan, the epidemiologist who serves as the director of One Health Trust, a Washington-based public health organization, argued that policymakers have to think harder about research funding strategies that can cut new antibiotics’ prices.

The current drug development process costs an average of more than $1.5 billion per drug, and that’s why the typical new antibiotic costs more than $10,000 per patient treated, Laxminarayan said.

Credit: Adobe Stock


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.